Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
|Videos|March 1, 2017
What's the Outlook for Medicare and High-Need Beneficiaries in 2017 and Beyond?
Tricia Neuman, senior vice president of the Henry J. Kaiser Family Foundation and director of the Foundation’s Program of Medicare Policy, was the guest speaker at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care.
Advertisement
Tricia Neuman, senior vice president of the Henry J. Kaiser Family Foundation and director of the Foundation’s Program of Medicare Policy, was the guest speaker at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Related to this article
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.
Phase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5